Cosmetic composition comprising yeast fermentation product or yeast polypeptide and troxerutin as active ingredients

Abstract

The present invention relates to a cosmetic composition comprising yeast fermentation or yeast polypeptide and troxerutin as active ingredients. The composition according to the present invention has an excellent inhibitory effect on the expression and production of nitric oxide (NO), interleukin-1 [alpha] (IL-1 [alpha]), interleukin-1 [beta] (IL-1 [beta]), interleukin-8 (IL-8), and prostaglandin E2 (PGE2), and thus can be effectively applied to cosmetics and external medicines for resisting inflammation, improving or preventing sensitive skin, or calming skin, and the like.

Description

Technical Field

[0001] The present invention relates to a cosmetic composition, a pharmaceutical composition, or a quasi-drug composition for anti-inflammation, improving or preventing sensitive skin, or calming skin, comprising yeast fermentation product or yeast polypeptide and troxerutin as active ingredients; and a method for calming skin or inhibiting inflammation, comprising the step of administering the composition to an individual. Background Art

[0002] The proportion of consumers with sensitive skin has been increasing recently, leading to a growing demand for cosmetics containing low-irritation ingredients or irritation-reducing ingredients. Sensitive skin is more susceptible to stinging, burning, and tingling than normal skin. Irritations can be caused by a variety of factors, including chemicals, stress, hormones, temperature fluctuations, and wind. These irritations are accompanied by inflammation, and the more sensitive the skin, the more likely it is to develop. Some cosmetic ingredients are known to cause skin inflammation, acne, swelling, and other problems.

[0003] Inflammation occurs when cells or tissues are damaged by specific factors, triggering a series of defensive actions to minimize their response and restore the damaged area to its original state. This triggers reactions in nerves, blood vessels, lymphatic vessels, humoral responses, and cells, ultimately causing pain, swelling, redness, fever, and other symptoms, leading to functional impairment. Inflammation can be caused by physical factors such as trauma, frostbite, burns, and radiation; chemical factors such as acids; and immunological factors such as antibody reactions. In addition, it can occur due to vascular damage or specific hormonal imbalances. As substances secreted by damaged cells cause vasodilation and increased intravascular permeability, antibodies, complement, plasma, and phagocytes flock to the inflamed tissue site, accelerating the inflammatory response and causing erythema.

[0004] Substances that have the effect of eliminating inflammation while also inhibiting the occurrence of additional inflammation are called anti-inflammatory agents. However, the non-steroidal anti-inflammatory agents (flufenamic acid, ibuprofen, benzydamine, indomethacin) and steroidal anti-inflammatory agents (prednisolone, dexamethasone) used for anti-inflammatory purposes so far have side effects in terms of skin safety and stability, and therefore their use as cosmetic raw materials is restricted. Moreover, compared with the expanding sensitive skin market, the reality is that there is a lack of ingredients with few side effects and significant effects. Therefore, it is necessary to develop an effective composition that can maximize the effects of preventing or improving sensitive skin, calming skin, or anti-inflammatory, while minimizing side effects.

[0005] The present inventors have conducted research on natural resources that are safer and have excellent skin-improving effects, and have derived a significant skin-soothing effect through a more detailed combination of specific natural-derived raw materials.

[0006] Prior art literature

[0007] Patent Literature

[0008] (Patent Document 0001) Korea 10-2411229B1

[0009] (Patent Document 0002) Korea 10-2532713B1 Summary of the Invention

[0010] Issues to be addressed

[0011] An object of the present invention is to provide a cosmetic composition for anti-inflammation, improving or preventing sensitive skin, or calming skin, which comprises yeast fermentation product or yeast polypeptide and troxerutin as active ingredients.

[0012] Another object of the present invention is to provide a pharmaceutical composition for preventing or treating inflammatory skin diseases, which comprises yeast fermentation product or yeast polypeptide and troxerutin as active ingredients.

[0013] Another object of the present invention is to provide a quasi-pharmaceutical composition for anti-inflammation, improving or preventing sensitive skin, or calming skin, which comprises yeast fermentation product or yeast polypeptide and troxerutin as active ingredients.

[0014] Solutions to the Problem

[0015] The details are as follows. On the other hand, the various descriptions and embodiments disclosed in the present invention can also be applied to various other descriptions and embodiments. That is, all combinations of the various elements disclosed in the present invention belong to the scope of the present invention. In addition, the scope of the present invention cannot be considered to be limited by the specific description of the following description. In addition, a large number of papers and patent documents are cited throughout the specification and their citations are marked. The disclosures of the cited papers and patent documents are incorporated into this specification by reference in their entirety to more clearly illustrate the level of the technical field to which the present invention belongs and the content of the present invention.

[0016] As one aspect of achieving the object of the present invention, the present invention provides a composition for anti-inflammation, improving or preventing sensitive skin, or calming skin, which comprises yeast fermentation product or yeast polypeptide and troxerutin as active ingredients.

[0017] For the purposes of this invention, the term "fermentation" refers to the process by which microorganisms decompose organic matter using their own enzymes, which is not part of the putrefaction process. Fermentation and putrefaction reactions proceed through similar processes, but if the decomposition produces useful substances, it is considered fermentation, while if it produces malodorous or harmful substances, it is considered putrefaction.

[0018] In the present invention, the method for obtaining the above-mentioned fermentation product is not particularly limited. However, the fermentation product can be obtained by inoculating the strain into a culture medium and culturing the culture medium at 20°C to 40°C with shaking for 1 to 200 hours, isolating the cells by centrifugation, and then disrupting the cells by ultrasonic treatment. Alternatively, the fermentation product can be obtained according to methods commonly used in the art or similar fields. In the present invention, the type of culture medium for inoculating the strain is not limited, as long as the strain is capable of fermentation.

[0019] In the present invention, the fermentation product obtained from the above-mentioned strain includes not only the fermented substance itself, but also all kinds of substances including the fermentation product produced by the above-mentioned strain, for example, the culture medium of the strain in which the strain and the culture coexist, the fermentation product of the strain filtered from the above-mentioned culture medium, the fermentation product obtained by sterilizing the strain from the above-mentioned culture medium and filtering it, the extract of the above-mentioned fermentation product or the culture medium containing it, the dilution solution of the above-mentioned fermentation product or its extract, the dried product of the above-mentioned fermentation product or its extract, the lysate of the bacterial body of the above-mentioned strain collected and crushed, etc.

[0020] In the present invention, the term "yeast polypeptide" refers to a collection of peptides or polypeptides of a certain size or larger that are functional and isolated from a culture or fermentation product obtained from a strain. For the purposes of the present invention, yeast polypeptides include fractions containing yeast polypeptides and may be used interchangeably with "yeast fractions" or "polypeptides extracted from a culture or fermentation product of a strain."

[0021] The term "fraction" in the present invention refers to a product obtained by a fractionation method of separating a specific component or a specific group from a mixture containing a plurality of constituent components.

[0022] In the present invention, the fractionation method for obtaining the above-mentioned fractions is not particularly limited and can be performed according to a method commonly used in the art. As a non-limiting example of the above-mentioned fractionation method, a method of obtaining fractions from the above-mentioned extract by treating an extract obtained from a culture or fermentation product of an extraction strain with a predetermined solvent can be cited.

[0023] In the present invention, the type of solvent used to obtain the above-mentioned fractions is not particularly limited, and any solvent known in the art can be used. Non-limiting examples of the above-mentioned fractionation solvent include polar solvents such as water and alcohol; and non-polar solvents such as hexane, ethyl acetate, chloroform, and dichloromethane. These can be used alone or in combination of two or more. When an alcohol is used as the above-mentioned fractionation solvent, it is preferably a C1 to C4 alcohol.

[0024] In the present invention, the method for separating fractions from the fermented product is not particularly limited, but the fractions can be obtained by concentrating and precipitating the lysate of the bacterial cells obtained by fermentation using and disrupting the strain, filtering only the supernatant, and then spray drying.

[0025] In the present invention, a peptide refers to a polymer of amino acid monomers artificially or spontaneously linked, a substance composed of two or more amino acids, and is referred to as a tripeptide, oligopeptide, or polypeptide depending on the number of amino acids. Specifically, in the present invention, a polypeptide may refer to a polypeptide comprising more than 100 amino acids, but is not limited thereto.

[0026] Specifically, the yeast may be a Saccharomyces cerevisiae strain, and the yeast fermentation product or yeast polypeptide may be derived from a Saccharomyces cerevisiae strain, respectively.

[0027] The term "Saccharomyces cerevisiae" used herein refers to a species of yeast belonging to the Saccharomycetaceae family and the genus Saccharomyces. This species has long been widely used and plays an important role in winemaking, baking, and brewing. The characteristics of Saccharomyces cerevisiae vary depending on the region in which it is grown and the natural environment, which can alter the activity of the strain and its fermented product. The Saccharomyces cerevisiae of the present invention can be derived from a fermentation broth, but is not limited thereto.

[0028] In one embodiment, the above-mentioned Saccharomyces cerevisiae strain can be a Saccharomyces cerevisiae strain deposited under the accession number KCTC 14780BP. In one embodiment of the present invention, it was confirmed that when a yeast fermentation product or yeast polypeptide derived from the above-mentioned Saccharomyces cerevisiae strain deposited under the accession number KCTC 14780BP is combined with troxerutin, or troxerutin and ubiquinol, the degree of inflammation inhibition is significantly increased compared to when the yeast fermentation product or yeast polypeptide is combined with other Saccharomyces cerevisiae strains.

[0029] In the present invention, the term "troxerutin" is a compound represented by the following chemical formula 1, which is a flavonoid component mainly found in various plants including Sophora japonica. Troxerutin has the characteristic of developing a dark color even when contained in a trace amount.

[0030] [Chemical Formula 1]

[0031]

[0032] In the present invention, when yeast ferment or yeast polypeptide is mixed with troxerutin, the effect of inhibiting inflammation is significantly increased compared with when each component is used alone, thereby having a major technical significance in showing a significant synergistic effect on improving or preventing sensitive skin, anti-inflammatory or calming skin.

[0033] In one embodiment of the present invention, the composition in which yeast fermentation or yeast polypeptide is mixed with troxerutin significantly increases the expression and production of nitric oxide (NO), interleukin-1α (IL-1α), interleukin-1β (IL-1β), interleukin-8 (IL-8) and prostaglandin E2 (PGE2) compared to when these ingredients are treated alone, thereby confirming the synergistic effect on inhibiting inflammatory factors (Examples 1 to 5).

[0034] There is no limitation on the mixing ratio of the yeast fermentation product or yeast polypeptide and troxerutin, as long as they are mixed to produce a synergistic effect.

[0035] In one embodiment, the yeast fermentation product or polypeptide and troxerutin can be mixed in a weight ratio of 200:1 to 1:1, 100:1 to 1:1, or 20:1 to 1:1, but is not particularly limited thereto. Due to the characteristic of troxerutin that it develops a dark color, when included within the above range, a synergistic effect on suppressing inflammation can be exerted while showing appropriate color development in the composition.

[0036] For example, the yeast fermentate and troxerutin may be mixed in a weight ratio of 100:1 to 1:1, 20:1 to 1:1, 15:1 to 1:1, 10:1 to 1:1, 7:1 to 1:1, or 5:1 to 1:1, but is not particularly limited thereto.

[0037] For example, the yeast polypeptide and troxerutin may be mixed in a weight ratio of 200:1 to 1:1, 150:1 to 1:1, 100:1 to 1:1, 50:1 to 1:1, 20:1 to 1:1, 10:1 to 1:1, or 7:1 to 1:1, but is not particularly limited thereto.

[0038] In one specific example, the sum of the contents of the yeast fermentation product or yeast polypeptide and troxerutin can be 0.0001 to 40 weight % (v / v) relative to the total weight of the composition, specifically, 0.001 to 10 weight % (v / v), but is not particularly limited thereto.

[0039] In the present invention, when the mixed sample of yeast fermentation product or yeast polypeptide and troxerutin is less than 0.0001 weight % relative to the total composition weight, the activity of the original purpose may not be fully achieved, so it may not be preferred, and when it exceeds 40 weight %, an increase in the effect as obvious as the increased content may not be expected, so it may not be economical.

[0040] In one embodiment, the composition may further comprise panthenol.

[0041] In the present invention, the term "panthenol" is a compound represented by the following chemical formula 2, which is an alcohol analog of vitamin B5 (pantothenic acid). Panthenol is rapidly oxidized to pantothenic acid in vivo and is a viscous, transparent liquid at room temperature.

[0042] [Chemical Formula 2]

[0043]

[0044] In one embodiment of the present invention, when the yeast fermentation product or the mixture of yeast polypeptide and troxerutin additionally contains ubiquinol, the expression and production of inflammatory factors including nitric oxide (NO), interleukin-1α (IL-1α), interleukin-1β (IL-1β), interleukin-8 (IL-8) and prostaglandin E2 (PGE2) are greatly inhibited, thereby confirming that the combination of the three ingredients has a significant synergistic effect.

[0045] There is no limitation on the mixing ratio of the yeast fermentation product or yeast polypeptide, troxerutin and panthenol, as long as they are mixed to produce a synergistic effect.

[0046] In one specific example, yeast fermentation product or yeast polypeptide, troxerutin and panthenol can be mixed in a weight ratio of 100 to 1:10 to 1:100 to 1, and when the weight ratio of each component is within this range, a suitable dosage form of the composition can be formed and better skin calming and anti-inflammatory effects can be exerted, but it is not particularly limited thereto.

[0047] For example, yeast fermentation product or yeast polypeptide, troxerutin and panthenol can be mixed in a weight ratio of 1-200:1:1-20, more specifically in a weight ratio of 1-100:1:1-20. As an example, they can be mixed in a weight ratio of 10:1:10, 1:1:10, or 100:1:10, but are not limited thereto.

[0048] In one specific example, the sum of the contents of the yeast fermentation product or yeast polypeptide, troxerutin and panthenol can be 0.0001 to 60 weight % (v / v) relative to the total weight of the composition, specifically 0.001 to 20 weight % (v / v), but is not particularly limited thereto.

[0049] In the present invention, when the mixed sample of yeast fermentation product or yeast polypeptide, troxerutin and panthenol is less than 0.0001 wt % relative to the total composition weight, the activity of the original purpose may not be fully achieved, and therefore it may not be preferred, and when it exceeds 60 wt %, an increase in effect as obvious as the increased content may not be expected, and therefore it may not be economical.

[0050] In the present invention, the term "anti-inflammatory" refers to all effects including the suppression of inflammation, generally referring to the prevention, treatment or improvement of inflammation. The inflammatory response is caused in order to enhance the repair system in the organism and reduce damage. If its degree is severe or long-term, it will cause cell damage, which can cause a variety of inflammatory diseases. Specifically, the generation of inflammation-related mediators, i.e., inflammatory factors or reactive oxygen species (ROS), can be suppressed. The above-mentioned inflammatory factors can be nitric oxide (Nitricoxide, NO), interleukin-1α (IL-1α), interleukin-1β (IL-1β), interleukin-8 (IL-8) or prostaglandin E2 (PGE2).

[0051] In the present invention, "skin calming" refers to relieving and stabilizing skin erythema or damaged skin areas caused by irritation. For example, skin calming can include relieving skin irritation (anti-irritation), reducing transepidermal water loss, and / or reducing redness. Anti-irritation can also mean that the condition of skin damaged by external irritation is improved or alleviated.

[0052] For the purposes of this invention, "sensitive skin" refers to skin that is more sensitive than normal skin to external stimuli or environmental changes such as allergic substances, making it more susceptible to irritation reactions or dermatitis. The causes of sensitive skin are diverse and complex, but may be due to genetic factors, resulting in congenitally sensitive skin, or to external factors such as harmful substances or stress, climate, seasonal changes, and work environment. Sensitive skin is generally caused by neurological overreactions, increased immune responses, and inflammatory reactions. Inflammatory reactions are primarily observed, but are not limited to these. Symptoms such as erythema, dry skin, stinging, itching, burning sensation, and inflammation may also be present, but are not limited to these.

[0053] "Improving sensitive skin" in the present invention refers to any action that reduces the occurrence of sensitive skin, or reduces the severity of symptoms such as erythema, dry skin, stinging, itching, burning, and inflammation caused by the occurrence of sensitive skin, or restores damaged skin. Furthermore, "preventing sensitive skin" in the present invention refers to any action that delays the occurrence of sensitive skin, or delays the symptoms such as erythema, dry skin, stinging, itching, burning, and inflammation caused by the occurrence of sensitive skin, by administering the above-mentioned composition.

[0054] Specifically, the composition of the present invention can inhibit the expression and generation of one or more inflammatory factors selected from the group consisting of nitric oxide (NO), interleukin-1α (IL-1α), interleukin-1β (IL-1β), interleukin-8 (IL-8) and prostaglandin E2 (PGE2). In one embodiment of the present invention, it was confirmed that when the composition of the present invention was added, the inhibitory effect on the generation of NO, IL-1α, IL-1β, IL-8 and PGE2 was significantly exerted, indicating that the composition of the present invention can provide excellent anti-inflammatory, improvement or prevention of sensitive skin, and calming skin effects.

[0055] The above-mentioned "expression" may include both gene expression and protein expression.

[0056] In the present invention, the term "about" may be given before a specific numerical value. The term "about" used in the present invention includes not only the exact number recorded after the term, but also a range that is almost that number or close to that number. Considering the context in which the number is given, it can be determined whether it is close to the specific number mentioned or whether it is almost that number. As an example, the term "about" can refer to a range of -10% to +10% of a numerical value. As another example, the term "about" can refer to a range of -5% to +5% of a given numerical value. However, it is not limited to this.

[0057] The composition of the present invention can be used as a cosmetic composition and can be formulated into various forms. The cosmetic composition of the present invention can be prepared in a dosage form selected from the group consisting of a solution, an external ointment, a cream, a foam, a nutritional lotion, a skin softener, a facial mask, a softening water, an emulsion, a makeup base, an essence, a soap, a liquid cleanser, a bath preparation, a sunscreen, a sunscreen oil, a suspension, an emulsion, a paste, a gel, a dew, a powder, a soap, a cleaning agent containing a surfactant, an oil, a powder foundation, an emulsion foundation, a wax foundation, a patch, and a spray, but is not limited thereto.

[0058] In addition, the cosmetic composition of the present invention may additionally contain one or more cosmetically acceptable carriers used in common skin cosmetics. Conventional ingredients such as oil, water, surfactants, moisturizers, lower alcohols, thickeners, chelating agents, pigments, preservatives, fragrances, etc. may be appropriately added, but are not limited thereto.

[0059] The cosmetically acceptable carrier contained in the cosmetic composition of the present invention varies depending on the dosage form.

[0060] When the dosage form of the present invention is an ointment, paste, cream or gel, as the carrier component, animal oil, vegetable oil, wax, paraffin, starch, tragacanth, cellulose derivatives, polyethylene glycol, silicone, bentonite, silicon dioxide, talc, zinc oxide or a mixture thereof can be used.

[0061] When the dosage form of the present invention is a powder or spray, lactose, talc, silicon dioxide, aluminum hydroxide, calcium silicate, polyamide powder or a mixture thereof can be used as a carrier component. In particular, when it is a spray, a propellant such as chlorofluorocarbons, propane / butane or dimethyl ether can be additionally contained.

[0062] When the dosage form of the present invention is a solution or emulsion, a solvent, solubilizer or emulsifier can be used as a carrier component, for example, water, ethanol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butyl glycol oil, in particular cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and sesame oil, glycerol fatty esters, polyethylene glycol or fatty acid esters of sorbitan can be used.

[0063] When the dosage form of the present invention is a suspension, as the carrier component, liquid diluents such as water, ethanol or propylene glycol, suspending agents such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitan esters and polyoxyethylene dehydrated sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar or tragacanth gum can be used.

[0064] When the dosage form of the present invention is soap, the carrier component may include alkali metal salts of fatty acids, fatty acid half ester salts, fatty acid protein hydrolyzates, isethionates, lanolin derivatives, fatty alcohols, vegetable oils and fats, glycerin, sugars, and the like.

[0065] Another aspect of the present invention provides a pharmaceutical composition for preventing or treating inflammatory skin diseases, comprising yeast fermentation product or yeast polypeptide and troxerutin as active ingredients. In one embodiment, the composition may further comprise panthenol.

[0066] In this case, the definitions of the above-mentioned "yeast fermentation product", "yeast polypeptide", "troxerutin" and "panthenol" are the same as above.

[0067] In the present invention, the term "inflammatory skin disease" is a general term for skin diseases with inflammation as the main lesion. The above-mentioned inflammatory skin diseases can be selected from the group consisting of seborrheic dermatitis, contact dermatitis, systemic lupus erythematosus, acne, eczema, acne, urticaria, psoriasis, lupus erythematosus, chronic simple lichen, intertrigo, exfoliative dermatitis and solar dermatitis, but are not limited thereto.

[0068] In the present invention, the term "prevention" refers to all actions to inhibit or delay the onset of inflammatory skin diseases by administering the composition of the present invention.

[0069] In the present invention, the term "treatment" refers to all actions that improve or beneficially change the symptoms of inflammatory skin diseases by administering the pharmaceutical composition of the present invention.

[0070] In the present invention, the pharmaceutical composition may additionally comprise a pharmaceutically acceptable carrier.

[0071] In the present invention, the term "pharmaceutically acceptable carrier" refers to a carrier or diluent that does not irritate the organism and does not inhibit the preventive or therapeutic activity and properties of the pharmaceutical composition of the present invention for inflammatory skin diseases. In compositions formulated as liquid solutions, the acceptable pharmaceutical carrier is sterile and suitable for the organism, and can be a mixture of saline, sterile water, Ringer's solution, buffered saline, albumin injection solution, dextrose solution, maltodextrin solution, glycerol, ethanol, and one or more thereof. Other conventional additives, such as antioxidants, buffers, and antibacterial agents, may be added as needed.

[0072] In addition, the pharmaceutically acceptable carrier of the present invention may include a non-naturally occurring carrier.

[0073] The pharmaceutical composition of the present invention can be administered in a single or multiple doses in a pharmaceutically effective amount.

[0074] In the present invention, the term "pharmaceutically effective amount" refers to a sufficient amount to prevent or treat a disease at a reasonable benefit / risk ratio applicable to medical prevention or treatment. The effective dosage level can be determined by the severity of the disease, the activity of the drug, the patient's weight, health, gender, the patient's sensitivity to the drug, the administration time, administration route and discharge rate of the composition of the present invention, the treatment period, the elements containing the drugs used in combination with or simultaneously with the composition of the present invention, and other factors well known in the medical field.

[0075] As another aspect, the present invention provides a method for preventing or treating inflammatory skin diseases, comprising administering a composition comprising a yeast fermentation product or a yeast polypeptide and troxerutin as active ingredients to an individual in need thereof. In one embodiment, the composition may further comprise panthenol.

[0076] In this case, the definitions of the above-mentioned "yeast fermentation product", "yeast polypeptide", "troxerutin", "panthenol", "inflammatory skin disease", "prevention" and "treatment" are the same as above.

[0077] In the present invention, individuals suspected of having the above-mentioned inflammatory skin diseases refer to all animals, including humans, that have already suffered from or may suffer from inflammatory skin diseases. By administering the pharmaceutical composition of the present invention to individuals suspected of having inflammatory skin diseases, the individuals can be effectively treated.

[0078] In the present invention, the term "administer" refers to introducing the pharmaceutical composition of the present invention into an individual suspected of having an inflammatory skin disease by any appropriate method, and the composition of the present invention can be administered by any general route that can reach the target in the organism. The administration route of the composition of the present invention is not particularly limited, but can be administered orally or parenterally. Specifically, it can be administered parenterally, and more specifically, it can be applied by applying to the skin (i.e., transdermal administration).

[0079] Specifically, the administration of the present invention can be carried out 1 to 4 times, 2 to 3 times or 2 times a day, but is not limited thereto. In addition, the administration of the present invention can be carried out for a period of more than 4 weeks, more than 8 weeks, 4 to 12 weeks or 8 to 12 weeks, but is not limited thereto.

[0080] Another aspect of the present invention provides a quasi-pharmaceutical composition for anti-inflammatory, improving or preventing sensitive skin, or calming skin, comprising yeast fermentation product or yeast polypeptide and troxerutin as active ingredients. In one embodiment, the composition may further comprise panthenol.

[0081] At this time, the definitions of the above-mentioned "yeast fermentation product", "yeast polypeptide", "troxerutin", "panthenol", "anti-inflammatory", "improving or preventing sensitive skin" and "calming skin" are the same as above.

[0082] The term "quasi-drug" as used in the present invention refers to an item used for the purpose of diagnosing, treating, improving, alleviating, treating or preventing diseases in humans or animals, and its effect is milder than that of a drug. For example, according to the Korean Pharmaceutical Affairs Act, quasi-drugs include, in addition to items used for the purpose of drugs, products used for the treatment or prevention of diseases in humans and animals, products that have mild or no direct effect on the human body, etc.

[0083] The quasi-drug composition of the present invention may be prepared in a form selected from the group consisting of shower gel, foam, soap, facial mask, ointment, cream, lotion, essence and spray, but is not limited thereto.

[0084] When the composition of the present invention is used as a quasi-medicine additive, the yeast fermentation product or yeast polypeptide, troxerutin and panthenol of the present application can be directly added or used together with other quasi-medicines or quasi-medicine ingredients, and can be appropriately used according to conventional methods. The mixing amount of the active ingredients can be appropriately determined according to the purpose of use.

[0085] Another aspect of the present invention provides a method for calming skin, comprising administering a composition comprising yeast fermentation product or yeast polypeptide and troxerutin as active ingredients to an individual in need thereof. In one embodiment, the composition may further comprise panthenol.

[0086] At this time, the definitions of the above-mentioned "yeast fermentation product", "yeast polypeptide", "troxerutin", "panthenol" and "skin calming" are the same as above.

[0087] Another aspect of the present invention provides a method for inhibiting inflammation, comprising administering a composition comprising yeast fermentation product or yeast polypeptide and troxerutin as active ingredients to an individual in need thereof. In one embodiment, the composition may further comprise panthenol.

[0088] In this case, the definitions of the above-mentioned "yeast fermentation product", "yeast polypeptide", "troxerutin" and "panthenol" are the same as above.

[0089] Another aspect of the present invention provides a method for improving or preventing sensitive skin, comprising administering a composition comprising yeast fermentation product or yeast polypeptide and troxerutin as active ingredients to an individual in need thereof. In one embodiment, the composition may further comprise panthenol.

[0090] At this time, the definitions of the above-mentioned "yeast fermentation product", "yeast polypeptide", "troxerutin", "panthenol" and "improvement or prevention of sensitive skin" are the same as above.

[0091] Another aspect of the present invention provides a composition comprising yeast fermentation product or yeast polypeptide and troxerutin as active ingredients for anti-inflammatory, improving or preventing sensitive skin, or calming skin. In one embodiment, the composition may further comprise panthenol.

[0092] Another aspect of the present invention provides the use of a composition comprising yeast fermentation product or yeast polypeptide and troxerutin as active ingredients for preventing or treating inflammatory skin diseases. In one embodiment, the composition may further comprise panthenol.

[0093] Effects of the Invention

[0094] The composition of the present invention comprising yeast fermentation product or yeast polypeptide and troxerutin as active ingredients is safe for the skin and has an excellent synergistic effect on inhibiting inflammatory factors and calming the skin, thereby having a high utilization rate for cosmetics and quasi-pharmaceuticals for combating inflammation, improving or preventing sensitive skin or calming the skin. DETAILED DESCRIPTION

[0095] Hereinafter, the present invention will be described in more detail by way of examples. These examples are provided to more specifically illustrate the present invention, and the scope of the present invention is not limited to these examples.

[0096] Preparation Example 1: Preparation of yeast (Saccharomyces cerevisiae KCTC14780BP) fermentation product and preparation of polypeptides extracted from yeast fermentation product and fractions containing the same

[0097] Preparation Example 1-1: Preparation of yeast fermentation product

[0098] The strain (Saccharomyces cerevisiae KCTC 14780BP, deposited by the Korea Type Culture Collection on November 16, 2021) was inoculated into the culture medium, cultured with shaking at 30°C for 3 days, and then separated by centrifugation. The bacteria were suspended in pure water and then broken by ultrasonic treatment to prepare a yeast fermentation product, which will be referred to as "yeast fermentation product" below. The fermentation product of the control group strain (Saccharomyces cerevisiae KCTC 7296) was prepared in the same manner, which will be referred to as "general yeast fermentation product" below.

[0099] Preparation Example 1-2: Preparation of polypeptides extracted from yeast fermentation products and fractions containing the same

[0100] The prepared yeast fermentation product was centrifuged again, and the dead cell fragments were concentrated. The product was then suspended in alcohol at a concentration twice that of the lysate, followed by centrifugation. The precipitated polypeptide fraction (polypeptide fraction) was separated from the lysate to prepare a fraction containing yeast polypeptides, hereinafter referred to as "yeast polypeptides." A fraction containing yeast polypeptides from a control strain (Saccharomyces cerevisiae KCTC 7296) was prepared in the same manner, hereinafter referred to as "general yeast polypeptides."

[0101] Example 1: Confirmation of the sedative effect (inhibition of inflammatory cytokine IL 1a expression) of troxerutin, yeast polypeptide and their mixture on sensitive stimulation

[0102] Using human keratinocytes, each sample was pretreated for one hour. After treatment with capsaicin, a known trigger of sensitivity, TRPV1, to create inflammatory conditions in sensitive skin, the effect of suppressing the production of sensitive stimuli (cytokines) was evaluated. Samples were diluted according to concentration and pretreated for one hour. Then, they were treated with 50 μM capsaicin. After incubation for 24 hours, cDNA was synthesized from the extracted RNA and used for qRT-PCR to evaluate the ability to suppress the production of the sensitive inflammatory cytokine (IL-1α), as shown below.

[0103] - Cytokine production inhibition ability (%) = {1-(gene expression fold 试验物质处理 / gene expression fold 试验物质处理 )}x 100

[0104] -Negative control group: 50 μM capsaicin

[0105] The results, as shown in Table 1, indicate that when yeast fermentation products or yeast peptides are treated together with troxerutin, a significant synergistic effect is exerted on the inhibition of IL-1α expression, compared to troxerutin alone, which has no inhibitory effect on the expression of the inflammatory factor IL-1α, and yeast peptides or yeast fermentation products alone, which have little effect. In particular, the addition of ubiquinol to the mixture demonstrated a greater synergistic effect on the inhibition of IL-1α.

[0106] In addition, compared with using general yeast polypeptides or general yeast fermentations, the IL-1α inhibitory effect was significantly increased when using fermentations of the specific Saccharomyces cerevisiae KCTC14780BP strain (yeast fermentations) or polypeptides (yeast polypeptides), thus confirming that even fermentations derived from strains with the same scientific name may have different effects depending on the specific strain.

[0107] [Table 1]

[0108] Treatment concentration IL1a inhibition rate (%) Troxerutin 1 -2.92 (no effect) Panthenol 10 11.78 Troxerutin + Panthenol 1+10 0.52 Yeast peptides 10 10.34 Yeast fermentation products 10 7.64 Troxerutin + Yeast Peptide 1+10 <![CDATA[22.86 * ]]> Troxerutin + yeast fermentation 1+10 <![CDATA[19.70 * ]]> Troxerutin + Panthenol + Yeast Peptide 1+10+10 <![CDATA[27.79 * ]]> Troxerutin + Panthenol + Yeast Ferment 1+10+10 <![CDATA[27.42 * ]]> Troxerutin + general yeast peptide 1+1 9.54 Troxerutin + general yeast fermentation 1+1 9.96 Troxerutin + Panthenol + General Yeast Peptide 1+10 11.59 Troxerutin + Panthenol + General Yeast Ferment 1+10 10.67

[0109] Example 2: Confirmation of the sedative effect of troxerutin, yeast polypeptide and their mixture on sensitive stimulation (inhibition of inflammatory cytokine IL-1b (IL-1β) expression)

[0110] Using human keratinocytes, each sample was pretreated for 1 hour with capsaicin, a known trigger of inflammatory cytokines, to evaluate the inhibitory effect on cytokine production. Samples were diluted according to concentration and pretreated for 1 hour before being treated with 50 μM capsaicin. After 24 hours of incubation, RNA was extracted and synthesized into cDNA, which was then used for qRT-PCR to evaluate the inhibitory effect on the production of the inflammatory cytokine (IL-1β), as shown below.

[0111] - Cytokine production inhibition ability (%) = {1-(gene expression fold 试验物质处理 / gene expression fold 试验物质处理 )}x 100

[0112] -Negative control group: 50 μM capsaicin

[0113] The results, as shown in Table 2 below, confirmed that when yeast polypeptide and troxerutin were administered together, the IL-1β inhibition rate was significantly increased compared to the yeast polypeptide alone treatment group which showed no effect on the expression inhibition of the inflammatory factor IL-1β, thereby exerting a synergistic effect.

[0114] In addition, when yeast polypeptides were used, the IL-1β inhibitory effect was more significantly increased, and when general yeast polypeptides were used, no IL-1β inhibitory effect was produced at all.

[0115] [Table 2]

[0116] Treatment concentration (ppm) IL1b inhibition rate (%) Troxerutin 1 23.86 Yeast peptides 1 -22.05 (no effect) Yeast peptides 10 -9.68 (no effect) Troxerutin + Yeast Peptide 1+1 <![CDATA[39.31 * ]]> Troxerutin + Yeast Peptide 1+10 <![CDATA[27.50 * ]]> Troxerutin + general yeast peptide 1+1 -1.27 (no effect) Troxerutin + general yeast peptide 1+10 -14.62 (no effect)

[0117] Example 3. Confirmation of the sedative effect (inhibition of inflammatory cytokine IL-8 expression) of troxerutin, yeast polypeptide, panthenol and their mixture on sensitive stimulation

[0118] Using human keratinocytes, each sample was pretreated for 1 hour with capsaicin, a known trigger of inflammatory responses, to evaluate the inhibitory effect on cytokine production. Samples were diluted according to concentration and pretreated for 1 hour before being treated with 50 μM capsaicin. After 24 hours of incubation, RNA was extracted and synthesized into cDNA, which was then used for qRT-PCR to evaluate the inhibitory effect on the production of the inflammatory cytokine (IL-8), as shown below.

[0119] - Cytokine production inhibition ability (%) = {1-(gene expression fold 试验物质处理 / gene expression fold 试验物质处理 )}x 100

[0120] -Negative control group: 50 μM capsaicin

[0121] [Table 3]

[0122] Treatment concentration (ppm) IL8 inhibition rate (%) Troxerutin 1 36.18 Panthenol 10 92.03 Yeast peptides 1 -18.34 (no effect) Yeast peptides 10 -47.93 (no effect) Troxerutin + Panthenol 1+10 -36.81 (no effect) Panthenol + Yeast Peptide 10+1 1.67 Troxerutin + Yeast Peptide 1+1 26.20 Troxerutin + Panthenol + Yeast Peptide 1+10+1 <![CDATA[120.36 * ]]> Troxerutin + Panthenol + General Yeast Peptide 1+10+1 -21.45 (no effect)

[0123] As shown in Table 3, it was confirmed that when yeast polypeptide was treated together with troxerutin and ubiquinol, the IL-8 expression inhibitory effect was significantly increased compared to the yeast polypeptide alone which had no effect on the expression of IL-8, an inflammatory factor, thereby exerting a synergistic effect.

[0124] In addition, when yeast polypeptides were used, the IL-8 inhibitory effect was significantly increased, and when general yeast polypeptides were used, no IL-8 inhibitory effect was produced at all.

[0125] Example 4. Confirmation of the sedative (inhibition of anti-inflammatory NO expression) effect of troxerutin, yeast polypeptide, panthenol, and a mixture of two or more thereof on sensitive stimuli

[0126] Using Raw 264.7 cells, we attempted to evaluate the inhibitory effects of troxerutin, yeast fermentation product, yeast peptide, panthenol, and mixtures of two or more of them on the production of NO, a known skin inflammatory factor.

[0127] The samples listed in Table 4 below were diluted according to their concentrations, pretreated for 30 minutes, and then treated with 2 mg / L LPS. After culturing for 24 hours, the NO production inhibition ability was evaluated using a NO quantification kit, as shown below.

[0128] - NO generation inhibition ability (%) = {1-(NO generation amount when sample is added / NO generation amount when no sample is added)} x 100

[0129] -Positive control group: 40mg / mL L-NMMA1

[0130] [Table 4]

[0131] Treatment concentration (pom) NO generation inhibition ability (%) Positive control group (L-MMA) 40mgimu 72.45 Troxerutin 1 -9.67 (no effect) Panthenol 10 -1.58 (no effect) Yeast peptides 10 6.6 Yeast peptides 100 11.4 Yeast fermentation broth 10 10.9 Troxerutin + Panthenol 1+10 <![CDATA[2.1 5 *]]> Troxerutin + Yeast Peptide 1+10 <![CDATA[26.30 * ]]> Troxerutin + Yeast Peptide 1+100 22.50 Troxerutin + yeast fermentation broth 1+10 <![CDATA[17.5 * ]]> Troxerutin + Panthenol + Yeast Peptide 1+10+10 <![CDATA[34.33 * ]]> Troxerutin + Panthenol + Yeast Peptide 1+10+100 <![CDATA[60.38 * ]]> Troxerutin + Panthenol + Yeast Fermentation Broth 1+10+10 <![CDATA[31.4 * ]]> Troxerutin + general yeast peptide 1+10 5.8 Troxerutin + general yeast peptide 1+100 6.9 Troxerutin + general yeast fermentation broth 1+10 6.4 Troxerutin + Panthenol + General Yeast Peptide 1+10+10 6.6 Troxerutin + Panthenol + General Yeast Peptide 1+10+100 8.4 Troxerutin + Panthenol + General Yeast Fermentation Broth 1+10+10 4.8

[0132] As shown in Table 4 above, the NO production inhibitory ability was recorded as a negative value in the group treated with troxerutin or panthenol alone, indicating no NO expression inhibitory effect at all. In addition, the group treated with yeast fermentation product or yeast polypeptide alone also showed insufficient NO production inhibitory effect.

[0133] In contrast, it was confirmed that when yeast polypeptide or yeast fermentation product is combined with troxerutin, and further when panthenol is additionally combined, the NO expression inhibitory effect is significantly enhanced compared to either alone, thereby exhibiting a synergistic effect on inflammation suppression and sedation.

[0134] However, when the control strain (Saccharomyces cerevisiae KCTC 7296) was used, the NO suppression effect was not significant even when the same components were combined. Therefore, it was confirmed that the NO suppression effect was more significantly enhanced when the fermentation product or polypeptide of the specific Saccharomyces cerevisiae KCTC 14780BP strain was used.

[0135] Example 5. Confirmation of the sedative (PGE2) effect of troxerutin, yeast polypeptide, panthenol and a mixture of two or more on sensitive stimuli

[0136] Using Raw 264.7 cells, we attempted to evaluate the inhibitory effects of troxerutin, yeast peptides, or their mixtures on PGE2 (prostaglandin E2) production. Meanwhile, it is known that PGE2 expression is approximately three times higher in sensitive skin.

[0137] The samples listed in Table 5 below were diluted according to their concentrations, pretreated for 30 minutes, and then treated with 500 ng / mL LPS. After culturing for 18 hours, the PGE2 production inhibitory ability was evaluated using a PGE2 quantification kit, as shown below.

[0138] - PGE2 production inhibitory ability (%) = (PGE2 production amount when sample is added / PGE2 production amount when no sample is added) x 100

[0139] - Positive control group: 100 μM L-NMMA1

[0140] [Table 5]

[0141] Treatment concentration (ppm) PGE2 inhibition rate (%) L-NMMA 100 μM 43.32 Troxerutin 1 14.72 Yeast peptides 10 4.14 Troxerutin + Yeast Peptide 1+10 <![CDATA[24.4 * ]]>

[0142] The results, as shown in Table 5 above, confirmed that compared with the troxerutin and yeast polypeptide alone-treated groups, which had no obvious inhibitory effect on PGE2 expression of inflammatory factors, when yeast polypeptide was treated together with troxerutin, the PGE2 inhibition rate increased significantly, thereby exerting a synergistic effect on suppressing inflammation.

[0143] From the above results, it can be confirmed that when the yeast fermentation product or yeast polypeptide of the present invention is combined with troxerutin or troxerutin and panthenol, a significant synergistic effect is exerted on alleviating sensitive skin, calming skin, and suppressing inflammation.

[0144] Based on the above description, those skilled in the art will appreciate that the present invention may be implemented in other specific ways without changing the technical concept or essential features of the present invention. It should be understood that the embodiments described above are illustrative and non-restrictive in all respects. The scope of the present invention should be interpreted as including the meaning and scope of the claims described below and all variations or modifications derived therefrom, rather than merely the detailed description above.

[0145] [Accession number]

[0146] Name of depository institution: Korea Type Culture Collection

[0147] Accession number: KCTC 14780BP

[0148] Date of preservation: 20211116.

Claims

1. A cosmetic composition for anti-inflammation, improving or preventing sensitive skin, or calming skin, comprising yeast fermentation product or yeast polypeptide and troxerutin as active ingredients.

2. The cosmetic composition according to claim 1, wherein The yeast fermentation product or yeast polypeptide is derived from a Saccharomyces cerevisiae strain.

3. The cosmetic composition according to claim 2, wherein The above strain is a Saccharomyces cerevisiae strain deposited under the accession number KCTC 14780BP.

4. The cosmetic composition according to claim 1, wherein The yeast fermentation product or yeast polypeptide and troxerutin are mixed in a weight ratio of 100:1 to 1:

1.

5. The cosmetic composition according to claim 1, wherein The cosmetic composition further comprises panthenol.

6. The cosmetic composition according to claim 5, wherein The yeast fermentation product or yeast polypeptide, troxerutin and panthenol are mixed in a weight ratio of 1-100:1:1-20.

7. The cosmetic composition according to claim 5, wherein Relative to the total weight of the composition, the total content of the yeast fermentation product or yeast polypeptide, troxerutin and panthenol is 0.0001 to 60 weight %.

8. The cosmetic composition according to claim 1, wherein The cosmetic composition inhibits the expression and production of one or more inflammatory factors selected from the group consisting of nitric oxide (NO), interleukin-1α (IL-1α), interleukin-1β (IL-1β), interleukin-8 (IL-8) and prostaglandin E2 (PGE2).

9. A pharmaceutical composition for preventing or treating inflammatory skin diseases, comprising yeast fermentation product or yeast polypeptide and troxerutin as active ingredients.

10. A quasi-pharmaceutical composition for anti-inflammation, improving or preventing sensitive skin, or calming skin, comprising yeast fermentation product or yeast polypeptide and troxerutin as active ingredients.

Images